Regeneron stays at neutral by Merrill

Regeneron Pharmaceuticals Inc: was kept at a neutral rating by Merrill Lynch analyst Hari Sambasivam. Merrill revised estimates due to amortization of a $25 million lump sum milestone payment from Sanofi-Aventis. The analyst increased the first-quarter 2006 loss-per-share estimate to $0.64 from $0.20 and its 2006 loss-per-share estimate to $2.25 from $1.66. Street estimates for loss per share range from $0.55 to $0.63 for the first quarter and $2.44 to $3.61 for the full year. Shares of the Tarrytown, N.Y., biotechnology company were up 13 cents, or 0.86%, at $15.25 on volume of 553,236 shares versus the three-month running average of 405,054 shares. (Nasdaq: REGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.